Yardena Samuels on RASA2 as Prognostic Biomarker in Melanoma

Yardena Samuels, PhD
Published: Tuesday, Jun 07, 2016


Yardena Samuels, PhD, Tenured Associate Professor, Department of Moleular Cell Biology, the Weizmann Institute of Science, Israel, discuses her lab’s discovery of a potential prognostic  biomarker in cutaneous sporadic melanoma.
 
Using a database of over 500 exomes and genomes, Samuels lab is functionally evaluating mutations in melanoma. This is to determine that the mutation is actually a driver, and to better understand what inhibitors work against it.   
 
They have discovered a new tumor suppressor gene called RASA2. This inhibits RAS, one of the most important oncogenes, says Samuels.
 
Over 30% of patients lose the expression of RASA2, which is correlated with reduced survival, making RASA2 a prognostic biomarker, says Samuels.
 
 
 
 
 

Yardena Samuels, PhD, Tenured Associate Professor, Department of Moleular Cell Biology, the Weizmann Institute of Science, Israel, discuses her lab’s discovery of a potential prognostic  biomarker in cutaneous sporadic melanoma.
 
Using a database of over 500 exomes and genomes, Samuels lab is functionally evaluating mutations in melanoma. This is to determine that the mutation is actually a driver, and to better understand what inhibitors work against it.   
 
They have discovered a new tumor suppressor gene called RASA2. This inhibits RAS, one of the most important oncogenes, says Samuels.
 
Over 30% of patients lose the expression of RASA2, which is correlated with reduced survival, making RASA2 a prognostic biomarker, says Samuels.
 
 
 
 
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: 13th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 28, 20182.0
Publication Bottom Border
Border Publication
x